A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Status:
Recruiting
Trial end date:
2027-04-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the improvement in time to prostate specific antigen
(PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of
apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration
resistant prostate cancer (NM-CRPC).